Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

599
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
599
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

164
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
164
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

121
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
121
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

226
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
226
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

652
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
652
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

527
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
527

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of catheter intervention for acute pulmonary emboli in a tertiary United Kingdom centre with an established Pulmonary Embolism Response Team (PERT).

CVIR endovascular·2026
Same author

Song complexity in suboscine birds: evolutionary drivers and ecological constraints.

Proceedings. Biological sciences·2026
Same author

Mid-Term Outcomes of Percutaneous Deep Venous Arterialization Using the LimFlow System.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists·2026
Same author

Tunnelled dialysis catheter tract haemorrhage during mechanical thrombectomy of right atrial line-associated thrombus and line removal: a case report.

CVIR endovascular·2025
Same author

Off-the-shelf Percutaneous Deep Vein Arterialization (pDVA).

VASA. Zeitschrift fur Gefasskrankheiten·2025
Same author

Migration Evolves in Response to Distinct Regimes of Climate Seasonality in Tropical Versus Temperate-Breeding Suboscine Birds.

Ecology and evolution·2025

Related Experiment Video

Updated: Aug 1, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.1K

Leg Ulcer Pathway Acceleration (LUPA) study.

Vanessa Livingstone1, Oscar Johnson1, Sujith Peta1

  • 1Department of Vascular Surgery, Guy's and St Thomas' Hospital, London, UK.

The British Journal of Surgery
|April 29, 2023
PubMed
Summary
This summary is machine-generated.

An accelerated leg ulcer care pathway significantly improved healing rates for venous leg ulcers. This new pathway demonstrated an 80% healing rate at 12 months, compared to 20% in the historical control group.

More Related Videos

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
08:05

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

4.2K
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.0K

Related Experiment Videos

Last Updated: Aug 1, 2025

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.1K
Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
08:05

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

4.2K
Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
04:09

Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers

Published on: March 3, 2023

3.0K

Area of Science:

  • Vascular Surgery
  • Wound Healing
  • Healthcare Management

Background:

  • Leg ulcers are a prevalent and costly condition, significantly impacting patient quality of life.
  • Current management of leg ulcers is inconsistent, leading to prolonged healing times.
  • There is a need for optimized care pathways to expedite leg ulcer treatment.

Purpose of the Study:

  • To design and implement an accelerated leg ulcer care pathway.
  • To improve patient outcomes in both community and hospital settings.
  • To reduce delays in leg ulcer healing.

Main Methods:

  • A new referral pathway was developed through interviews, focus groups, and workshops.
  • Investigation and treatment protocols were informed by clinical guidelines.
  • Patient outcomes were compared between the new pathway and a historical control group.

Main Results:

  • The accelerated pathway enrolled 110 patients, with a mean age of 55.7 years.
  • 80% of patients on the accelerated pathway achieved ulcer healing at 12 months.
  • This represents a significant improvement compared to the 20% healing rate in the historical control group (P < 0.001).

Conclusions:

  • The implementation of an accelerated leg ulcer care pathway leads to significantly improved ulcer healing rates.
  • This pathway offers a more effective approach to managing leg ulcers compared to historical controls.
  • Optimized care pathways are crucial for enhancing patient outcomes in leg ulcer management.